Cleveland BioLabs Provides Update on Barda Development Proposal
January 23, 2014 07:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, N.Y., Jan. 23, 2014 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the Biomedical Advanced Research and Development Authority ("BARDA") has terminated...
Cleveland BioLabs Announces $7 Million At-The-Market Registered Direct Offering
January 14, 2014 09:05 ET
|
Cleveland BioLabs, Inc.
BUFFALO, N.Y., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that it has entered into definitive agreements with two institutional investors to purchase an...
Cleveland BioLabs Announces Departure of Jean Viallet to Assume Oncology Development Leadership Role at Leading Biopharmaceutical Company
December 18, 2013 10:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, N.Y., Dec. 18, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today reported that Chief Development Officer, Jean Viallet, MD will leave the Company to assume an oncology...
Cleveland BioLabs to Present at Oppenheimer 24th Annual Healthcare Conference
December 03, 2013 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, N.Y., Dec. 3, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the Company is scheduled to present at the Oppenheimer & Co. 24th Annual Healthcare...
Cleveland BioLabs and Incuron Announce Poster Presentation at Society of Neuro-Oncology Meeting
November 21, 2013 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, N.Y., Nov. 21, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Incuron, LLC, a joint venture between CBLI and Bioprocess Capital Ventures today announced a poster...
Cleveland BioLabs Reports Third Quarter 2013 Financial Results and Development Progress
November 06, 2013 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, N.Y., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today reported financial results and development progress for the third quarter and nine-month periods ended...
Cleveland BioLabs to Report Third Quarter 2013 Financial Results and Provide Operational Update on November 6
October 29, 2013 08:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, N.Y., Oct. 29, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that on November 6, 2013, it will report its financial results for the third quarter and...
Panacela Signs Contract for Approximately $4.6 Million With Russian Ministry of Industry and Trade for Development of Mobilan; Announces Appointment of Michael Fonstein as CEO and President
October 23, 2013 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, N.Y., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that Panacela Labs, Inc., a majority-owned subsidiary of CBLI, has entered into a contract valued...
Cleveland BioLabs Optimizes Operational Focus on Clinical Development
October 18, 2013 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, N.Y., Oct. 18, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) announced today that because of maturation of its development pipeline and a reduced need for certain services,...
Cleveland BioLabs Signs Contract With Russian Ministry of Industry and Trade for Clinical Development of Entolimod (CBLB502)
October 16, 2013 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, N.Y., Oct. 16, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that its wholly-owned Russian subsidiary, BioLab 612, LLC, has entered into a three-year contract...